Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.

Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, Abu-Khalaf M, Cai L, Pohlmann P, Mohebtash M, Kamugisha L, Isaacs C.

Contemp Clin Trials Commun. 2018 May 7;10:190-192. doi: 10.1016/j.conctc.2018.05.012. eCollection 2018 Jun.

2.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J.

Cancer Chemother Pharmacol. 2018 Jun 7. doi: 10.1007/s00280-018-3610-z. [Epub ahead of print]

PMID:
29882016
3.

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.

Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L.

Breast Cancer Res Treat. 2018 Jun;169(2):333-340. doi: 10.1007/s10549-017-4653-2. Epub 2018 Feb 2.

PMID:
29396664
4.

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.

Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB.

J Oncol Pract. 2017 Dec;13(12):e1012-e1020. doi: 10.1200/JOP.2017.022731. Epub 2017 Oct 19.

PMID:
29048991
5.

A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia.

Fratamico RS, Strickland KS, Uppal G, Abu-Khalaf M.

Clin Breast Cancer. 2018 Jun;18(3):e295-e298. doi: 10.1016/j.clbc.2017.06.013. Epub 2017 Jul 4. No abstract available.

PMID:
28735676
6.

Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.

Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP.

J Natl Compr Canc Netw. 2017 Mar;15(3):346-354.

PMID:
28275035
7.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

8.

Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.

Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, Cristofanilli M, Yang H.

Breast Cancer Res Treat. 2017 Jan;161(1):83-94. doi: 10.1007/s10549-016-4026-2. Epub 2016 Oct 22.

PMID:
27771841
9.

Chemotherapy for Elderly Ovarian Cancer Patients.

Muralikrishnan S, Hatzis C, Katz A, Santin A, Schwartz PE, Abu-Khalaf MM.

Gynecol Obstet (Sunnyvale). 2016 Aug;6(8). pii: 397. Epub 2016 Aug 31.

10.

Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.

Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE.

Eur J Gynaecol Oncol. 2016;37(2):199-203.

PMID:
27172745
11.

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools.

Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L.

Oncotarget. 2016 Apr 19;7(16):22064-76. doi: 10.18632/oncotarget.8017.

12.

Patient preferences regarding incidental genomic findings discovered during tumor profiling.

Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW.

Cancer. 2016 May 15;122(10):1588-97. doi: 10.1002/cncr.29951. Epub 2016 Mar 11.

13.

Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications.

Oprea AD, Russell RR, Russell KS, Abu-Khalaf M.

J Cardiothorac Vasc Anesth. 2017 Dec;31(6):2206-2226. doi: 10.1053/j.jvca.2015.06.020. Epub 2015 Jun 12. Review. No abstract available.

PMID:
26952170
14.

New Strategies in Breast Cancer: Immunotherapy.

Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G.

Clin Cancer Res. 2016 May 1;22(9):2105-10. doi: 10.1158/1078-0432.CCR-15-1315. Epub 2016 Feb 11.

15.

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.

Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN.

Clin Cancer Res. 2016 Jul 1;22(13):3249-59. doi: 10.1158/1078-0432.CCR-15-2021. Epub 2016 Feb 3.

16.

Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.

Su KW, Hall J, Soulos PR, Abu-Khalaf MM, Evans SB, Mougalian SS, Rutter CE, Davidoff AJ, Gross CP.

J Geriatr Oncol. 2016 Jan;7(1):15-23. doi: 10.1016/j.jgo.2015.11.002. Epub 2015 Dec 17.

PMID:
26704661
17.

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.

Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L.

Breast Cancer Res Treat. 2015 Dec;154(3):533-41. doi: 10.1007/s10549-015-3631-9. Epub 2015 Nov 14.

18.

Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer.

Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, Evans SB.

Clin Breast Cancer. 2016 Feb;16(1):59-62. doi: 10.1016/j.clbc.2015.09.008. Epub 2015 Sep 21.

PMID:
26483315
19.

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer.

Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L.

Clin Cancer Res. 2016 Jan 1;22(1):26-33. doi: 10.1158/1078-0432.CCR-14-3304. Epub 2015 Aug 18.

20.

Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.

Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN.

Int J Cancer. 2016 Feb 1;138(3):747-57. doi: 10.1002/ijc.29808. Epub 2015 Aug 31.

21.

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.

Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB.

Cancer. 2015 Aug 1;121(15):2544-52. doi: 10.1002/cncr.29348. Epub 2015 Apr 22.

22.

Intrasplenic Arterial Aneurysms during Pregnancy.

Abu-Khalaf MM, Al-Ameer SM, Smadi MM, Qatawneh A, Smara OA, Hadidy AT.

Case Rep Obstet Gynecol. 2015;2015:248141. doi: 10.1155/2015/248141. Epub 2015 Feb 24.

23.

Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility study.

Bulloch KJ, Irwin ML, Chagpar AB, Pusztai L, Killelea BK, Horowitz NR, Hofstatter EW, Abu-Khalaf MM, DiGiovanna M, Chung GG, Sanft TB.

J Oncol Pract. 2015 Mar;11(2):e170-6. doi: 10.1200/JOP.2015.005173. Erratum in: J Oncol Pract. 2015 May;11(3):265.

PMID:
25784577
24.

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.

Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM.

Breast Cancer Res Treat. 2015 Feb;150(1):157-67. doi: 10.1007/s10549-015-3292-8. Epub 2015 Feb 17.

PMID:
25687356
25.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.

Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN.

Cancer. 2015 Jun 1;121(11):1817-26. doi: 10.1002/cncr.29254. Epub 2015 Feb 3.

26.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.

BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326.

27.

Impact of financial burden of cancer on survivors' quality of life.

Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB.

J Oncol Pract. 2014 Sep;10(5):332-8. doi: 10.1200/JOP.2013.001322. Epub 2014 May 27.

PMID:
24865220
28.

Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.

Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM.

Int J Gynecol Cancer. 2014 Mar;24(3):528-33. doi: 10.1097/IGC.0000000000000085.

PMID:
24557436
29.

Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy.

Chang B, Sokhn J, James E, Abu-Khalaf M.

Clin Breast Cancer. 2014 Apr;14(2):e61-4. doi: 10.1016/j.clbc.2013.11.007. Epub 2013 Nov 21. No abstract available.

PMID:
24373644
30.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.

31.

The cost of breast cancer screening in the Medicare population.

Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X.

JAMA Intern Med. 2013 Feb 11;173(3):220-6. doi: 10.1001/jamainternmed.2013.1397.

32.

Cancer therapy related cardiotoxicity.

Abu-Khalaf MM, Bader F.

Curr Cardiol Rev. 2011 Nov;7(4):213. No abstract available.

33.

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.

Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Br J Cancer. 2012 Apr 24;106(9):1543-50. doi: 10.1038/bjc.2012.132.

34.

DTCs/CTCs in breast cancer: five decades later.

Alsamarai S, Abu-Khalaf MM, Harris LN.

Recent Results Cancer Res. 2012;195:217-25. doi: 10.1007/978-3-642-28160-0_20. Review.

PMID:
22527509
35.
36.

Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.

Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD.

BMC Cancer. 2010 Jul 2;10:349. doi: 10.1186/1471-2407-10-349.

37.

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675. Epub 2010 Jan 6.

38.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Br J Cancer. 2010 Jan 5;102(1):134-43. doi: 10.1038/sj.bjc.6605448. Epub 2009 Nov 17.

39.

Uncommon incidental pseudoaneurysm. Diagnostic and management challenges.

Hadidy AM, Samara OA, Takrouri HS, Al-Ryalat NT, Al-Smady MM, Ryalat ST, Abu-Khalaf MM.

Saudi Med J. 2009 Aug;30(8):1037-43.

PMID:
19668884
40.

Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients.

Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM.

Curr Opin Ophthalmol. 2009 Jul;20(4):308-17. doi: 10.1097/ICU.0b013e32832c9007. Review.

PMID:
19491683
41.

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.

Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L.

J Clin Oncol. 2009 Jul 20;27(21):3430-6. doi: 10.1200/JCO.2008.18.4085. Epub 2009 May 26.

42.

Anthracycline-induced cardiotoxicity: risk assessment and management.

Abu-Khalaf MM, Harris L.

Oncology (Williston Park). 2009 Mar;23(3):239, 244, 252. No abstract available.

43.

Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter.

Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR.

Ann Surg Oncol. 2009 Mar;16(3):697-702. doi: 10.1245/s10434-008-0268-5. Epub 2009 Jan 9.

PMID:
19132447
44.

Intussusception: Jordan University Hospital experience.

Saleem MM, Al-Momani H, Abu Khalaf M.

Hepatogastroenterology. 2008 Jul-Aug;55(85):1356-9.

PMID:
18795688
45.

The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.

Abu-Khalaf MM, Harris L.

Breast Cancer Res Treat. 2009 Apr;114(3):513-5. doi: 10.1007/s10549-008-0145-8. Epub 2008 Aug 2. No abstract available.

PMID:
18677560
46.

Breast sentinel lymph node dissection before preoperative chemotherapy.

Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR.

Arch Surg. 2008 Jul;143(7):692-9; discussion 699-700. doi: 10.1001/archsurg.143.7.692.

PMID:
18645113
47.

Discrete-time nonlinear HJB solution using approximate dynamic programming: convergence proof.

Al-Tamimi A, Lewis FL, Abu-Khalaf M.

IEEE Trans Syst Man Cybern B Cybern. 2008 Aug;38(4):943-9. doi: 10.1109/TSMCB.2008.926614.

PMID:
18632382
48.

Adaptive critic designs for discrete-time zero-sum games with application to H(infinity) control.

Al-Tamimi A, Abu-Khalaf M, Lewis FL.

IEEE Trans Syst Man Cybern B Cybern. 2007 Feb;37(1):240-7.

PMID:
17278575
49.

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.

Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA.

Breast Cancer Res Treat. 2007 Sep;104(3):341-9. Epub 2006 Oct 19.

PMID:
17051423
50.

Predictors of morbidity and mortality in the surgical management of hydatid cyst of the liver.

Daradkeh S, El-Muhtaseb H, Farah G, Sroujieh AS, Abu-Khalaf M.

Langenbecks Arch Surg. 2007 Jan;392(1):35-9. Epub 2006 Sep 20.

PMID:
17021792

Supplemental Content

Loading ...
Support Center